Ina Research Inc
TSE:2176
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Ina Research Inc
TSE:2176
|
JP |
|
S
|
Shandong Sinobioway Biomedicine Co Ltd
SZSE:002581
|
CN |
|
M
|
Mira Pharmaceuticals Inc
NASDAQ:MIRA
|
US |
|
Chorus Aviation Inc
TSX:CHR
|
CA |
|
UOB-Kay Hian Holdings Ltd
SGX:U10
|
SG |
|
Eagle Graphite Inc
XTSX:EGA
|
CA |
|
D
|
Drillcon AB
STO:DRIL
|
SE |
|
R
|
Redtone Digital Bhd
KLSE:REDTONE
|
MY |
Balance Sheet
Balance Sheet Decomposition
Ina Research Inc
Ina Research Inc
Balance Sheet
Ina Research Inc
| Mar-2013 | Mar-2014 | Mar-2015 | Mar-2016 | Mar-2017 | Mar-2018 | Mar-2019 | Mar-2020 | Mar-2021 | Mar-2022 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
341
|
420
|
499
|
145
|
237
|
916
|
382
|
464
|
656
|
972
|
|
| Cash Equivalents |
341
|
420
|
499
|
145
|
237
|
916
|
382
|
464
|
656
|
972
|
|
| Total Receivables |
302
|
408
|
564
|
489
|
652
|
382
|
601
|
441
|
408
|
473
|
|
| Accounts Receivables |
302
|
408
|
564
|
489
|
652
|
382
|
599
|
441
|
407
|
472
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
2
|
1
|
|
| Inventory |
816
|
724
|
423
|
460
|
509
|
692
|
767
|
858
|
1 167
|
1 378
|
|
| Other Current Assets |
191
|
219
|
181
|
28
|
67
|
92
|
104
|
157
|
159
|
346
|
|
| Total Current Assets |
1 650
|
1 771
|
1 667
|
1 121
|
1 466
|
2 082
|
1 855
|
1 920
|
2 391
|
3 168
|
|
| PP&E Net |
2 432
|
2 335
|
2 312
|
1 490
|
1 386
|
1 324
|
1 330
|
1 487
|
1 477
|
1 457
|
|
| PP&E Gross |
2 432
|
2 335
|
2 312
|
1 490
|
1 386
|
1 324
|
1 330
|
1 487
|
1 477
|
1 457
|
|
| Accumulated Depreciation |
2 820
|
2 993
|
3 167
|
3 291
|
3 365
|
3 341
|
3 432
|
3 215
|
3 298
|
3 417
|
|
| Intangible Assets |
65
|
46
|
22
|
7
|
4
|
3
|
10
|
20
|
36
|
29
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
8
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
60
|
35
|
60
|
32
|
32
|
33
|
41
|
40
|
131
|
207
|
|
| Total Assets |
4 207
N/A
|
4 186
0%
|
4 062
-3%
|
2 650
-35%
|
2 888
+9%
|
3 442
+19%
|
3 242
-6%
|
3 467
+7%
|
4 035
+16%
|
4 861
+20%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
261
|
256
|
273
|
309
|
359
|
300
|
394
|
307
|
477
|
553
|
|
| Accrued Liabilities |
0
|
78
|
0
|
0
|
68
|
142
|
158
|
137
|
188
|
267
|
|
| Short-Term Debt |
200
|
175
|
575
|
307
|
447
|
497
|
100
|
100
|
100
|
0
|
|
| Current Portion of Long-Term Debt |
436
|
399
|
233
|
140
|
333
|
339
|
139
|
160
|
188
|
192
|
|
| Other Current Liabilities |
700
|
696
|
480
|
397
|
381
|
711
|
653
|
936
|
1 085
|
1 667
|
|
| Total Current Liabilities |
1 597
|
1 604
|
1 585
|
1 152
|
1 586
|
1 989
|
1 444
|
1 640
|
2 038
|
2 678
|
|
| Long-Term Debt |
765
|
735
|
592
|
898
|
679
|
678
|
986
|
969
|
908
|
765
|
|
| Minority Interest |
113
|
60
|
0
|
25
|
11
|
17
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
60
|
55
|
60
|
51
|
51
|
48
|
51
|
59
|
57
|
54
|
|
| Total Liabilities |
2 535
N/A
|
2 455
-3%
|
2 307
-6%
|
2 126
-8%
|
2 327
+9%
|
2 733
+17%
|
2 480
-9%
|
2 668
+8%
|
3 004
+13%
|
3 498
+16%
|
|
| Equity | |||||||||||
| Common Stock |
685
|
685
|
685
|
685
|
685
|
685
|
685
|
685
|
685
|
685
|
|
| Retained Earnings |
414
|
476
|
466
|
748
|
716
|
574
|
524
|
487
|
255
|
332
|
|
| Additional Paid In Capital |
601
|
601
|
601
|
601
|
601
|
601
|
601
|
601
|
601
|
346
|
|
| Other Equity |
28
|
30
|
3
|
15
|
9
|
3
|
0
|
0
|
0
|
0
|
|
| Total Equity |
1 672
N/A
|
1 732
+4%
|
1 755
+1%
|
524
-70%
|
561
+7%
|
709
+26%
|
762
+7%
|
799
+5%
|
1 031
+29%
|
1 364
+32%
|
|
| Total Liabilities & Equity |
4 207
N/A
|
4 186
0%
|
4 062
-3%
|
2 650
-35%
|
2 888
+9%
|
3 442
+19%
|
3 242
-6%
|
3 467
+7%
|
4 035
+16%
|
4 861
+20%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
3
|
3
|
3
|
3
|
3
|
3
|
3
|
3
|
3
|
3
|
|